Evidence map›Paper›PMID 41331048›Full record

ArticleNPJ precision oncology2025

Comprehensive characterization and targeted treatment of a pediatric epithelioid glioblastoma with a rare TRIM24-NTRK2 fusion.

Simon Keane, Ida Sjöberg, Lily Deland, Angelica Lindlöf, Thomas Olsson Bontell, Teresia Kling, Malin Blomstrand, Henrik Fagman, Jonas A Nilsson, Daniel Nilsson and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Simon Keane *Clinical Genetics and Genomics, Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Ida Sjöberg *Sahlgrenska Centre for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Lily DelandClinical Genetics and Genomics, Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Angelica LindlöfSchool of Bioscience, University of Skövde, Systems Biology Research Environment, University of Skövde, Skövde, Sweden.
Thomas Olsson BontellDepartment of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Teresia KlingSahlgrenska Centre for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Malin BlomstrandDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
Henrik FagmanDepartment of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Jonas A NilssonSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Daniel NilssonDepartment of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
Magnus SabelChildhood Cancer Centre, Queen Silvia Children´s Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
Helena CarénSahlgrenska Centre for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden. helena.caren@gu.se.
Frida AbelClinical Genetics and Genomics, Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden. frida.abel@gu.se.

Funding

ALF ALFGBG-965446Cancerfonden 211540FKCancerfonden 211695PJCancerfonden 222199 PJMary Béves Stiftelse for children's cancer research SKSjöbergstiftelsen 2020-160Swedish Childhood Cancer Foundation KP2021-0010Swedish Childhood Cancer Foundation PD2023-0032Swedish Childhood Cancer Foundation PR2022-0047The Swedish Research Council 2021-01483
6 · The paper itself

Abstract

High-grade gliomas are one of the most lethal cancers and the leading cause of cancer-related mortality in children. Standard treatment typically involves resection, chemotherapy and radiation, yet offer limited improvement in survival rates. Targeted therapies are emerging to show effect in solid tumors harboring tyrosine-kinase activating fusion genes. Here, we present a thorough characterization of an epithelioid glioblastoma in a six-year-old patient, with four relapses and a variety of different treatment strategies. We identified a rare TRIM24::NTRK2 fusion in the primary tumor, which enabled a targeted TRK-inhibitor treatment. Our findings show that the TRIM24::NTRK2 fusion initially had oncogenic abilities, but this became less imperative as the tumor evolved. A general drug resistance to TRK-inhibition was documented. This study addresses the complex and adaptive nature of pediatric epithelioid glioblastomas and highlights the need for continued molecular profiling from relapses and various tumor regions to enable multitarget treatment approaches.

Identifiers

PMID41331048
PMCPMC12678440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.